Technical Data
B0807-06H
Bcl-2 (B Cell Leukemia 2) (PE)
Description:
The human bcl-2 gene family plays a central role in lymphoid system cell survival. Continuous expression of bcl-2 protein is critical for preventing apoptosis of mature peripheral B and T cells.

Applications:
Suitable for use in Flow Cytometry and Western Blot. Other applications not tested.

Recommended Dilution:
Flow Cytometry: 1:50
Western Blot: Unconjugated
Optimal dilutions to be determined by the researcher..

Flow Cytometry Protocol:
Incubations and washes using a buffer containing 0.5% Tween-20 to permeabolize cell, were done at RT.
1. Cultured Nalm-6 human tumor cells were fixed for 20 min with 0.5% freshly prepared buffered formaldehyde after which they were washed two times.
2. Five x 10e5 cells per tube were incubated 45 minutes with 80ul of B0807-06H at a 1:50 dilution.
3. Cells were then washed three times, fixed and analyzed using a BD FACstar plus.
4. Cells stained positive with a mean shift of 0.78 log 10 fluorescent units when compared to a tube where cells were pre blocked with 20ul of 0.5mg/ml B0807-06E.

Storage and Stability:
May be stored at 4C before opening. DO NOT FREEZE! Stable at 4C as an undiluted liquid. Dilute only pror to immediate use. Freezing R-Phycoerythrin (PE) conjugates will result in a substantial loss of enzymatic activity
TypeIsotypeCloneGrade
MabIgG17H161Affinity Purified
SizeStorageShippingSourceHost
120Tests4C Do Not FreezeBlue IceHumanMouse
Concentration:
~0.5mg/ml
Immunogen:
Human bcl-2 peptide 41-54.
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.5, 0.2% BSA, 0.04% sodium azide, 15% glycerol. Labeled with R-Phycoerythrin (PE).
Specificity:
Recognizes the intracellular 26kD of the human Bcl-2 protein.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. F. Pezzella, et al, (1990) Am J Pathol 137: 225-232. I.A. Doussis, et al, (1993) Am J Clin Pathol 99: 663-667. 2. S. Cory, (1995) Annu Rev Immunol 13: 513-543.